Kadmon’s graft-versus-host treatment gets FDA approval
Kadmon Holdings Inc.
KDMN,
+7.61%
said Friday that Rezurock, its treatment of chronic graft-versus-host disease (cGVHD) in adjusts and pediatric patients older than 12 was approved by the Food and Drug Administration. The biopharmaceutical company’s…
